

Novabiochem® Letters: 3/11



NEW Arginine mimetics for Fmoc SPPS

Fmoc-Agp(Boc)₂-OH

Fmoc-Phe(bis-Boc-4-guanidino)-OH

Arginine is unique amongst proteogenic amino acids in that the basic sidechain guanidino group remains positively charged across all pHs found in biological systems. Arginine residues often play pivotal roles in mediating receptor interactions, protein-protein recognition and maintaining protein structure through salt bridge formation. Furthermore, many therapeutically relevant proteases display a preference for arginine residues in their endogenous substrates. Consequently, arginine mimetics are important tools

Inside this issue

NEW Homo amino-acid analogs NEW Fmocylation reagent NEW Bi-functional PEG building blocks NEW Protected Cys derivative for NCL for studying the role of arginine in biological functions and for developing enzyme inhibitors as potential therapeutics.

The Novabiochem® brand is, therefore, pleased to expand our range of arginine analogs with the introduction of Fmoc-Agp(Boc)₂-OH and Fmoc-Phe-bis-Boc-4-guanidino)-OH. These derivatives are compatible with standard Fmoc SPPS methods. Removal of the side-chain Boc groups is effected during the course of the TFA cleavage reaction.

852336 Fmoc-Agp(Boc)₂-OH
NEW

852337 Fmoc-Phe(bis-Boc-4-guanidino)-OH
NEW

852267 Fmoc-homoArg(Pbf)-OH

NEW Homo amino-acid analogs

Fmoc-hCys(Trt)-OH

Fmoc-hPhe-OH

We are pleased to offer Fmoc-hCys(Trt)-OH and Fmoc-hPhe-OH as the latest additions to our range of side-chain homologs of Fmoc-protected amino acids.

852266 NEW	Fmoc-hCys(Trt)-OH	1 g 5 g
852328 NEW	Fmoc-hPhe-OH	1 g 5 g

The Novabiochem® brand's other homo analogs:

852267 Fmoc-homoArg(Pbf)-OH

852059 Fmoc-Hse(Trt)-OH

NEW Fmocylation reagent

Fmoc-Oxyma

Features & Benefits

5 g

1 g

5 g

1 g

- Eliminates the formation of β -alanyl-related impurities during Fmocylation reactions
- Ideal for Fmocylation of hindered amino acids

The synthesis of Fmoc-protected amino acids using Fmoc-OSu has been found to lead to products contaminated with Fmoc- β -Ala-OH and Fmoc- β -Ala-Aaa-OH [1, 2], which arise through base-catalyzed ring opening of the succinimide moiety, followed by the Lossen rearrangement (Figure 1) and subsequent formation of β -alanine. Unfortunately, such impurities are almost impossible to remove and often the researcher has no choice but to use contaminated Fmoc-amino acids in peptide synthesis, which results in incorporation of unwanted β -Ala into their desired sequence.

Fig. 1: Lossen rearrangement.

5 g

1 g

The problem is most serious with hindered amino acids such as Aib, where the formation of β -Ala related by-products has been observed to occur to the extent of 3.1 %. Fortunately, this problem can now be overcome through the use of the novel Fmocylation reagent, Fmoc-Oxyma [3]. This compound cleanly protects amino acids suspended in

THF/water/Na₂CO₃ at 40 °C.

851094	Fmoc-Oxyma	5 g
NEW		25 g

NEW Bifunctional PEG building blocks

N-Biotinyl-NH-PEG₁₁-COOH

Features & Benefits

- Improves solubility of biotinylated peptide
- Reduces steric hindrance between biotin and peptide
- Compatible with standard Fmoc peptide synthesis protocols

N-Biotinyl-NH-PEG $_{11}$ -COOH is a new building block for the preparation of biotin-labeled peptides, which incorporates a hydrophilic 40-atom spacer. It is prepared from a highly-purified monodisperse PEG to ensure homogeneous products free from contaminating oligomers. In contrast to similar linkers based on polydisperse PEG, this reagent gives products that are single chemical entities which can be characterized and purified using standard techniques.

N-Biotinyl-NH-PEG $_{11}$ -COOH is particularly suited to the synthesis of hydrophobic biotinylated peptides, as the inclusion of the polar PEG spacer should significantly improve their solubility in aqueous buffer. The spacer also reduces steric hindrance between the peptide and avidin, leading to better biotin binding. Furthermore, the hydrophilic nature of the PEG should prevent the spacer group from becoming buried in the hydrophobic pocket of target proteins.

852340 NEW	N-Biotinyl-NH-PEG ₁₁ -COOH	250 mg 1 g
851029	N-Biotinyl-NH-PEG ₂ -COOH	500 mg 1 a

NEW Protected Cys derivative for NCL

Fmoc-Thz-OH

Features & Benefits

- · Reagent for introduction of Thz residue
- N-terminal Thz residue can be converted to cysteine by treatment with methoxyamine

Fmoc-Thz-OH is a building block for the intoduction of thiaproline (Thz) during Fmoc SPPS. Thz has been employed as a masked cysteine residue to prevent self-ligation during native chemical ligation reactions (NCL) of

N₃-PEG-COOK (8 atoms)

Features & Benefits

851205

852338

NEW

Fmoc-Thz-OH

· Introduced using standard activation methods

Na-PEG-COOK (8 atoms)

- Compatible with Fmoc SPPS
- Terminal amine unmasked by reduction with phosphines or thiols

N₃-PEG-COOK is the latest addition to the Novabiochem ®brand's range of PEG-based building blocks for solid phase peptide synthesis. It can be introduced using standard coupling methods, such as PyBOP® or HBTU, and is compatible with TFA cleavage protocols, provided thiols are omitted from the cocktail [4]. Reduction of the azido group to an amine can be effected using phosphines [5, 6], thiols [7] or SnCl₂ [8].

NEW	N3 125 COOK (O diollis)	1 g		
The Novabiochem® brand's other azido derivatives:				
851021	N ₃ -PEG ₇ -COOH (33 atoms)	1 g		
851097	ε-Azidocaproic acid	1 g 5 g		
852320	Fmoc-L-β-azidoalanine	100 mg 500 mg		
852321	Fmoc-L-γ-azidohomoalanine	100 mg 500 mg		
852322	Fmoc-L- δ -azidonorvaline	100 mg 500 mg		
852326	Fmoc-L-ε-azidonorleucine	250 mg		

peptide thioesters bearing an N-terminal Cys residue [9]. Once ligation is complete, the N-terminal Cys residue of the resultant peptide is unmasked by ring opening the Thz residue by treatment with methoxyamine, thereby enabling its subsequent ligation to another peptide thioester fragment.

A selection of the Novabiochem® brand's other cysteine derivatives:				
852006	Fmoc-Cys(Acm)-OH	5 g 25 g 100 g		
852022	Fmoc-Cys(tButhio)-OH	5 g 25 g 100 g		
852008	Fmoc-Cys(Trt)-OH	5 g 25 g 100 g		

5 g 25 g

250 mg

References

- 1. M. Obkircher, et al. (2008) J. Pept. Sci., 14, 763.
- 2. A. Isidro-Llobet, et al. (2007) Biopolymers, 88, 733.
- 3. S. N. Khattab, et al. (2010) Eur. J. Org. Chem., 3275.
- 4. P. E. Schneggenburger, et al. (2010) J. Pept. Sci., 16, 10.
- a) J. T. Lundquist & J. C. Pelletier (2001) Org. Lett., 3, 781; b) J. T. Lundquist & J. C. Pelletier (2002) Org. Lett., 4, 3219.
- 6. N. Nepomniaschiy, et al. (2008) Org. Lett., 10, 5243.
- 7. M. Meldal, et al. (1997) *Tetrahedron Lett.*, **38**, 2531.
- 8. H. Katayama, et al. (2008) Tetrahedron Lett., 49, 5492.
- M. Villain, et al. in "Peptides: The wave of the future, Proc. Second Int.&t 17th American Peptide Symposium", M. Lebl &t R A. Houghten (Eds), American peptide Society, 2001, pp. 107.

Product prices and availability are subject to change. Products are warranted only to meet the specifications set forth on their label/packaging and/or certificate of analysis at the time of shipment or for the expressly stated duration. NO OTHER WARRANTY WHETHER EXPRESS, IMPLIED OR BY OPERATION OF LAW IS GRANTED. The products are intended for research purposes only and are not to be used for drug or diagnostic purposes, or for human use. Merck KGaA's products may not be resold or used to manufacture commercial products without the prior written approval of Merck KGaA. All sales are subject to Merck KGaA's complete Terms and Conditions of Sale (or if Sold through an affiliated company of Merck KGaA, such affiliated company's complete Terms and Conditions of Sale). Novabiochem* and PyBOP® are a registered trademarks of Merck KGaA in Australia, Germany, Japan, Switzerland, the United Kingdom, and the United States.

©Copyright 2011 Merck KGaA, Darmstadt, Germany. All rights reserved.